Prespecified subgroup analyses showed that primary surgery conferred greater benefits for patients with stage III disease and ...

New research suggests that an antibody-drug conjugate may offer practice-changing, patient-friendly treatment of blastic ...

Updated, longer-term results from the COMMANDS trial show a promising trend toward improved overall survival with ...

A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable ...

On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a ...

At the 2025 ASCO (American Society of Clinical Oncology) Annual Meeting, Dr. Armenian presented findings from the session ...

Results from the Phase Ib/II CARTITUDE-1 trial demonstrated that a single infusion of Carvykti delivered durable, ...

Investigators created a prognostic digital pathology-based AI score to identify a subset of patients with clinically high-risk prostate cancer more likely to benefit from the addition of abiraterone ...

Adding immunotherapy to chemotherapy after surgery for stage 3 colon cancer may help decrease recurrence and death rate by 50 ...

A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't ...

ASCO Data Shows New Therapy Keeps Myeloma Patients in Remission for 5+ Years. Here's what you need to know about the ...

Cancer organizations are urging researchers, oncologists, and other stakeholders to advocate for cancer research.